Tscan therapeutics appoints heather savelle as vice president, investor relations

Waltham, mass., oct. 05, 2021 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a biopharmaceutical company focused on the development of t-cell receptor (tcr) engineered t cell therapies (tcr-t) for the treatment of patients with cancer, today announced the appointment of heather savelle as vice president, investor relations. ms. savelle brings to tscan over 20 years of experience in corporate communications and investor relations.
TCRX Ratings Summary
TCRX Quant Ranking